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Long-term safety of a weekly and monthly subcutaneous
buprenorphine depot (CAM2038) in the treatment of
adult out-patients with opioid use disorder
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Edward V. Nunes9 , Jakob Billeskov Jansen10, Lars Chemnitz Frey11, Bernd Weber12,
Paul Haber13,14, Sonia Oosman15, Sonnie Kim15 & Fredrik Tiberg16
ABSTRACT
Aims To assess the long-term safety of subcutaneous buprenorphine (CAM2038) weekly and monthly depots.
Design Phase 3, open-label, observational, multi-centre 48-week trial (ClinicalTrials.gov NCT02672111).
Setting Twenty-six out-patient sites (United States, United Kingdom, Hungary, Denmark, Sweden, Germany,
Australia) between 14 December 2015 and 12 April 2017. Participants Two hundred and twenty-eight adults with
opioid use disorder; 227 received CAM2038 (37 initiated onto CAM2038 and 190 converted from sublingual
buprenorphine). Interventions CAM2038 weekly (8, 16, 24 or 32 mg) or monthly (64, 96, 128 or 160 mg) with flex-
ible dosing and individualized titration utilizing multiple CAM2038 weekly and monthly doses. Measurements Safety
variables, urine toxicology samples and self-reported illicit opioid use were collected at each visit. Participants were admin-
istered a patient satisfaction survey at months 6 and 12, completed by 162 of 227 (71.4%) participants. Findings The
study treatment periodwas completed by 167 of 227 (73.6%) participants. At least one treatment-emergent adverse event
(TEAE) was reported by 143 of 227 (63.0%) participants, of whom60 of 227 (26.4%) reported as being drug-related. Most
of the TEAEs, reported by 128 of 227 (56.4%) of participants, were mild or moderate in intensity. Injection-site reactions
were reported by 46 of 227 (20.3%) participants, with most [45 of 46 (97.8%)] reported as mild to moderate. Five partic-
ipants (2.2%) discontinued the study drug due to a TEAE, two cases (0.9%) of which were injection-site-related. No serious
adverse events were attributed to the study drug. At the end of the study, the percentage of opioid-negative urine tests com-
bined with self-reports was 63.0% (17 of 37) in new-to-treatment participants and 82.8% (111 of 190) for participants
converted from sublingual buprenorphine. Participants reported high levels of satisfaction with CAM2038.
Conclusions Subcutaneous buprenorphine delivered weekly ormonthly (CAM2038) waswell tolerated, with a systemic
safety profile consistent with the known profile of sublingual buprenorphine. CAM2038 weekly and monthly was associ-
ated with high retention rates and low levels of illicit opioid use throughout this study.
Keywords Buprenorphine, CAM2038, depot, long-term safety, opioid use disorder, Phase 3 trial.
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INTRODUCTION
Opioid use disorder (OUD) and opioid-related overdose
deaths are escalating global health problems [1–3]. In
2015, approximately 35 million people globally used
opioids for non-medical purposes [4]. Opioid use disorder
is a chronic, relapsing disorder causing significant mental,
physical and social problems, including transmission of
infectious diseases, unintentional overdose and criminal
activity [5–7]. Treatment with sublingual buprenorphine
(SL BPN) is effective in treating moderate or severe OUD
[5–7]; however, SL BPN is associated with significant
limitations, including non-adherence to prescribed daily
dosing schedule, burdens and stigma to patients and
health-care providers, diversion and misuse of medication
and accidental paediatric exposure [8–14]. Additionally,
supervised administration of SL BPN, if applied, increases
the cost and inconvenience of treatment for service pro-
viders and patients.
CAM2038, a weekly or monthly buprenorphine (BPN),
is a ready-to-use, extended-release injection designed for
flexible and individualized treatment of OUD from day 1
of treatment through long-term maintenance therapy.
The injection depot is engineered to immediately and
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spontaneously start to form amatrix for extended release of
BPN upon exposure to the subcutaneous environment. Ad-
ministration of CAM2038 is performed by health-care pro-
fessionals, thereby effectively reducing risks of non-medical
use or misuse, non-adherence and diversion.
In a 24-week randomized controlled study, compared
with SL BPN, CAM2038 demonstrated non-inferiority for
the proportion of participants with no evidence of illicit opi-
oid use, and met superiority on the cumulative distribution
function (CDF) for no illicit opioid use with comparable
systemic safety [15]. This open-label, multi-centre, multi-
national study was conducted to assess the long-term
safety of a flexible dosing regimen of weekly and monthly
CAM2038 during a 48-week period in adult out-patients
with OUD. Effectiveness (unsanctioned substance use,
withdrawal and craving measures) and treatment reten-
tion were assessed as secondary outcomes.
METHODS
Study design
This Phase 3, open-label, multi-centre, 48-week study
(ClinicalTrials.gov NCT02672111) was conducted at 26
sites in the United States, the United Kingdom, Hungary,
Denmark, Sweden, Germany and Australia to assess the
safety of CAM2038 weekly and monthly (Supporting
information, Table S1). The study was approved by the
Institutional Review Board in the United States or national
equivalent at respective countries and conducted in
compliance with Good Clinical Practice regulations and
guidelines, the ethical principles originated from the
Declaration of Helsinki, the International Council for
Harmonisation guidance, and all applicable local regula-
tions. Signed informed consent forms were obtained from
each participant before undergoing any study procedure.
Participants
Males and females aged 18–65 years (inclusive) with a
current diagnosis of moderate or severe OUD based on
the Diagnostic and Statistical Manual of Mental Disorders,
5th edn (DSM-5) criteria [16] or a past medical history of
dependence, currently treated with SL BPN, or seeking to
initiate BPN treatment and had had no BPN treatment for
≥ 60 days were enrolled. Female participants of childbear-
ing potential were required to use contraception through-
out the study (screening to follow-up) and could not be
breastfeeding. Key exclusion criteria comprised moderate-
to-severe substance use disorder defined by DSM-5 for
any substance other than opioids, caffeine or nicotine;
chronic pain requiring opioid treatment; hypersensitivity
or allergy to naloxone (NX; for participants receiving a
SL BPN/NX test dose), BPN or excipients of CAM2038;
exposure to any investigational drug 4 weeks prior to
screening; acquired immune deficiency syndrome; and re-
cent or current suicidal ideation or behaviour based on the
Columbia Suicide Severity Rating Scale (C-SSRS). Addi-
tional exclusion criteria are provided in the Supporting
information.
Study treatment and participant care
Medications were supplied as prefilled syringes of
CAM2038 weekly (50 mg/ml) and CAM2038 monthly
(356 mg/ml) (Table 1). CAM2038 weekly was provided
at dose strengths of 8, 16, 24 or 32 mg BPN base and
CAM2038 monthly was provided at dose strengths of
64, 96, 128 or 160 mg BPN base. Investigators could
titrate doses and adjust dosing intervals (weekly or
monthly) as needed for each participant. Subcutaneous
injections were administered to the buttock; re-injection
in the same location was avoided for the duration of the
study for CAM2038 monthly and for at least 8 weeks for
CAM2038 weekly.
The study included screening (weeks –3 to –1), treat-
ment (weeks 1–48) and follow-up (weeks 49–53) phases.
Following screening, eligible participants initiated subcuta-
neous injections of CAM2038 weekly or monthly, based
on their current treatment status. On study day 1, new-
to-treatment participants in mild-to-moderate withdrawal
received a 4-mg test dose of SL BPN/NX and were observed
for at least 1 hour. Tolerability was confirmed by a lack of
precipitated withdrawal symptoms, assessed clinically. Par-
ticipants were then administered a single dose of 16-mg
CAM2038 weekly and, if needed, received an additional
8-mg weekly dose titration on day 4. Based on the investi-
gator’s clinical judgement, participants could receive addi-
tional 8-mg weekly doses on days 5–7, up to a maximum
dose of 40 mg during week 1. Participants who were not
Table 1 Dose conversion for participants converting from
sublingual buprenorphine or sublingual buprenorphine/naloxone
to CAM2038 weekly and monthly.
SL BPN or
SL BPN/NX CAM2038 weeklya CAM2038 monthlyb
≤ 6 mg 8 mg (0.16 ml) NA
8–10 mg 16 mg (0.32 ml) 64 mg (0.18 ml)
12–16 mg 24 mg (0.48 ml) 96 mg (0.27 ml)
18–24 mg 32 mg (0.64 ml) 128 mg (0.36 ml)
26–32 mg NA 160 mg (0.45 ml)
NA = not applicable; NX = naloxone; SC = subcutaneous; SL BPN = sublin-
gual buprenorphine. aParticipants were allowed dose adjustments as needed
with CAM2038 weekly at scheduled visits or with 8 mg CAM2038 SC sup-
plemental injections at unscheduled visits up to a maximum weekly dose of
40 mg per week. bParticipants who needed additional temporary
buprenorphine were allowed a maximum of two supplemental injections
of 8 mg CAM2038 weekly per week; dose adjustments could be made at in-
vestigator discretion at scheduled visits.
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new-to-treatment were converted directly to CAM2038
weekly or monthly at a dose corresponding to their current
daily SL BPN or SL BPN/NX treatment (Table 1). Adjust-
ments of CAM2038 dose, either increases or decreases,
were permitted during the 48-week treatment period as in-
dicated based on the investigator’s clinical judgement.
Temporary dose adjustments with supplemental 8-mg
CAM2038 weekly were allowed as needed during both
weekly and monthly dosing intervals (maximum weekly
dose of 40 mg per week for participants on weekly dosing
andmaximum two supplemental doses per week for partic-
ipants on monthly dosing). Transitions from CAM2038
weekly to CAM2038monthly or vice versa were permitted
as per the investigator’s clinical judgement, in consultation
with the participant, at any time during the treatment
phase.
Psychosocial components of care including case
management and counselling were provided at each site
in accordance with local procedures. At the end of the
treatment phase, participants were converted to usual care
(SL BPN/NX) and followed for an additional 4 weeks
(follow-up phase).
Outcome measures and participant assessments
The primary objective was to evaluate the safety and
tolerability of CAM2038. Safety was assessed by
treatment-emergent adverse event (TEAE) and serious
AE (SAE) monitoring, injection-site examinations, clinical
laboratory tests, vital signs, electrocardiogram (ECG),
physical examinations, C-SSRS and pregnancy reporting.
All AEs were collected throughout the study until 14 days
after the follow-up visit (or 30 days after early termina-
tion). TEAEs and SAEs were followed until resolution or
stabilization of the condition. AEs were coded by primary
system organ class and preferred term, according to the
Medical Dictionary for Regulatory Activities, version
18.0.
Injection-site examinations were performed during
each scheduled visit by monitoring reactions—including
erythema, swelling and pain—and by participant inter-
view and investigator assessments. Level of injection-site
pain was assessed using a numerical pain scale. The inten-
sity of injection-site symptoms was graded as mild, moder-
ate or severe; an injection-site reaction was defined as the
presence of ≥ 1 moderate or severe symptom or ≥ 2 mild
symptoms.
Laboratory tests including haematological, coagula-
tion, biochemical and urinalysis profiles were performed
at screening and the end-of-study visit. Vital signs were
collected at scheduled visits following ≥ 3 minutes of rest.
Twelve-lead ECGs were performed at screening, after the
first CAM2038 administration, at time of increasing a
CAM2038 dose, after taking QT-extending drugs or
cytochrome P450 3A4 inhibitors and at the end of the
study. Evaluations with the baseline/screening version of
the C-SSRS were performed at screening and at all subse-
quent visits with the since-last-visit C-SSRS.
Measurement of illicit opioid and other substance use
was based on urine toxicology, evaluated using immunoas-
say for opioids and other substances using reflex quantita-
tive confirmation methods (liquid chromatography/mass
spectrometry) for opioids and self-reported drug use. Urine
toxicology samples were collected at each visit; specimen
authenticity was ensured by temperature measurement
or direct observation as needed. Treatment period comple-
tion was defined as participants who completed the day
337 visit.
Withdrawal symptoms were measured by participant
self-assessment using the Subjective Opioid Withdrawal
Scale (SOWS) and the clinician-administered Clinical
Opioid Withdrawal Scale (COWS) [17]. Cravings, or desire
and need to use, were assessedwith a unipolar 100-mmvi-
sual analogue scale (VAS) ranging from 0 (no desire/need
to use) to 100 mm (strongest possible desire/need to use)
since the last visit [18,19].
At months 6 and 12, a subset of participants in both
groups completed a patient-reported experience question-
naire rating seven characteristics of their BPN treatment
(ease of travel, daily adherence, privacy, lack of need for
daily medication or regular visits to pharmacy, accidental
paediatric exposure, access by others to medications) on
Likert scales (1 was ‘not important’; 7 was ‘extremely im-
portant’). Participants also rated their overall experience
with CAM2038 compared with prior SL BPN treatment
on a five-unit scale from ‘much worse’ to ‘much better’.
The subsample reflects participants recruited in the latter
half of the recruitment period.
Statistics
The overall safety population included all participants who
received ≥ 1 dose of CAM2038; the full exposure safety
population included all participants treated with
CAM2038 for 48 weeks. Efficacy was assessed in all partic-
ipants who received ≥ 1 dose of CAM2038 and provided
some post-baseline efficacy measurements. No imputation
was provided for missing data. Data analyses were per-
formed using SAS version 9.2 (SAS Institute, Cary, NC,
USA). Continuous data were summarized using descriptive
statistics, and categorical data were presented using
frequencies and percentages. Baseline was recorded as
the last observed measurement before the first dose of
CAM2038; if multiple observations were noted prior to
the first dose, baseline was defined as the average of these
observations.
Safety analyses required 100 participants with
≥ 48 weeks of CAM2038 exposure. Assuming a 50%
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discontinuation rate, enrolment of approximately 228
participants was planned to ensure a sufficient number of
participants with appropriate duration of CAM2038
exposure for safety assessments.
RESULTS
Participants and treatment exposure
Between 14 December 2015 and 12 April 2017, 228 par-
ticipants were enrolled; one participant withdrew consent
prior to the first dose of CAM2038, and 227 participants
received ≥ 1 dose of CAM2038. Prior to study entry, a ma-
jority of participants (59.0%) used heroin as their primary
illicit opioid (51.1% of participants converted from treat-
mentwith SL BPN/NX and 100% of new-to-treatment par-
ticipants) (Table 2). Other drugs were prescription opioid
analgesics, ‘street’ BPN and methadone. Most participants
(84%; n = 190) were converted from treatment with SL
BPN and 16% (n = 37) were new to treatment (Fig. 1).
Individualization of treatment resulted in participants
Table 2 Demographics and baseline clinical characteristics (overall safety population).
Characteristic
Converted from SL BPN treatment
n = 190
New to BPN treatment
n = 37 Overall N = 227
Age, years, mean (SD) 41.3 (9.6) 41.8 (9.4) 41.4 (9.6)
Sex
Male 119 (62.6) 24 (64.9) 143 (63.0)
Female 71 (37.4) 13 (35.1) 84 (37.0)
BMI, kg/m2, mean (SD) 26.7 (5.8) 25.3 (5.3) 26.5 (5.8)
Region
Australia 23 (12.1) 1 (2.7) 24 (10.6)
Europe 76 (40.0) 0 76 (33.5)
United States 91 (47.9) 36 (97.3) 127 (55.9)
Employment status
Employed 106 (55.8) 13 (35.1) 119 (52.4)
Unemployed 77 (40.5) 23 (62.2) 100 (44.1)
Other 7 (3.7) 1 (2.7) 8 (3.5)
Marital status
Married 59 (31.1) 6 (16.2) 65 (28.6)
Single 102 (53.7) 30 (81.1) 132 (58.1)
Other 29 (15.3) 1 (2.7) 30 (13.2)
Residential status
Own 55 (28.9) 2 (5.4) 57 (25.1)
Rent 121 (63.7) 33 (89.2) 154 (67.8)
Other 14 (7.4) 2 (5.4) 16 (7.0)
Arrest and conviction history
Previously arrested 48 (25.3) 10 (27.0) 58 (25.6)
Felony conviction 15 (7.9) 11 (29.7) 26 (11.5)
Misdemeanour conviction 18 (9.5) 5 (13.5) 23 (10.1)
None 108 (56.8) 11 (29.7) 119 (52.4)
Other 1 (0.5) 0 1 (0.4)
Substance use history
Opioid use disorder (DSM-5) diagnosis 157 (82.6)a 37 (100.0) 194 (85.5)
Time to first opioid abuse, years, mean (SD) 14.7 (8.5) 15.7 (9.0) 14.8 (8.6)
Time to first diagnosis, years, mean (SD) 9.8 (7.6) 10.0 (8.6) 9.8 (7.8)
Heroin as primary opioid of use 97 (51.1) 37 (100.0) 134 (59.0)
Baseline withdrawal and craving scores, mean (SD)b
Clinical Opioid Withdrawal Scale (COWS)c 2.0 (2.7) 10.6 (3.7) 3.4 (4.3)
Subjective Opioid Withdrawal Scale
(SOWS)d
4.7 (8.1) 27.1 (15.3) 8.3 (12.7)
Opioid craving; desire-to-use VASe 11.7 (24.2) 74.8 (24.8) 22.0 (33.7)
Opioid craving; need-to-use VASf 11.7 (23.8) 76.3 (24.9) 22.3 (33.8)
Unless otherwise noted, data presented as n (%). BMI = body mass index; BPN = buprenorphine; DSM-5 = Diagnostic and Statistical Manual of Mental Dis-
orders, 5th edn; OUD= opioid use disorder; SD= standard deviation; SL BPN= sublingual buprenorphine; VAS = visual analogue scale. a33 participants had a
history of OUD; befficacy population; cscores range from0 (nowithdrawal) to 48 (severewithdrawal); dscores range from0 (nowithdrawal) to 64 (severe with-
drawal); escores range from 0 (no desire to use) to 100mm (maximum desire to use since the last visit); and fscores range from 0 (no need to use) to 100 mm
(maximum need to use since the last visit).
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receiving either weekly or monthly CAM2038 doses rang-
ing from 8 to 40 mg weekly and 64 to 160 mg monthly
(Table 3).
Overall, the mean [standard deviation (SD)] duration of
CAM2038 exposure was 39.1 (16.2) weeks (range = 1.1–
49.9 weeks). A total of 5196 CAM2038 injections were
administered with a mean of 22.9 injections per partici-
pant over the course of the study, corresponding to 170.2
participant-exposure years.
A total of 75 of 227 (33.0%) participants were treated
exclusively with CAM2038 weekly throughout the study,
77 of 227 (33.9%) were treated exclusively with
CAM2038 monthly and 75 of 227 (33.0%) started weekly
and transitioned later to monthly doses. Of 190 partici-
pants receiving SL BPN at enrolment, 50 (26.3%)
converted to, and remained on, CAM2038 weekly; 63
(33.2%) converted to CAM2038 weekly and subsequently
transitioned to CAM2038 monthly; and 77 (40.5%) con-
verted to CAM2038 monthly. Of the 37 new-to-treatment
participants, 25 (67.6%) commenced and remained on
CAM2038 weekly, while 12 (32.4%) transitioned from
CAM2038 weekly to CAM2038 monthly.
Temporary dose adjustments with supplemental 8-mg
weekly CAM2038 accounted for 301 (5.8%) of the total
Figure 1 Consolidated Standards of Reporting Trials (CONSORT) diagram. aParticipants who completed the treatment period were those who
completed a day 337 visit. BPN = buprenorphine; SL BPN = sublingual buprenorphine
Table 3 Highest CAM2038 dose reached by regimen.
Regimen
CAM2038
dose (mg)
Total
CAM2038
N = 227 n (%)
Weekly, n = 154 8 5 (3.2)
16 28 (18.2)
24 70 (45.5)
32 49 (31.8)
40a 2 (1.3)
Monthly, n = 151 64 36 (23.8)
96 56 (37.1)
128 37 (24.5)
160 22 (14.6)
aMaximum dose for participants receiving CAM2038weekly was 40mg per
week.
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number of injections throughout the 48 weeks of
treatment. The majority of participants who required dose
adjustments received ≤ 3 temporary dose adjustments
throughout the 48 weeks of treatment.
Safety
In the overall safety population, 143 of 227 (63.0%) par-
ticipants experienced ≥ 1 TEAE, with 60 of 227 (26.4%)
participants experiencing an AE considered as being
related to study medication (Table 4). Rates of TEAEs were
similar between participants in the full exposure safety
population (n = 156) and the overall safety population
(n = 227). The most common TEAEs occurring in ≥ 5%
of participants were pain, swellingor erythema at the injec-
tion site; nasopharyngitis; headache; nausea; urinary tract
infection; and vomiting. The overall incidence of TEAEs
was higher in participants converted from SL BPN
(68.9%) compared with new-to-treatment participants
(32.4%); this also included a numerical difference in the in-
cidence of injection-site TEAEs (23.2 versus 5.4%). A total
of 12 of 227 (5.3%) participants experienced ≥ 1
treatment-emergent SAE; none occurred at the injection
site or in association with an injection-site reaction, and
none were determined to be related to study drug. No
deaths occurred during the study.
Most TEAEs were mild or moderate in intensity
[reported by 128 of 227 (56.4%) of participants]; 15 of
227 (6.6%) participants had a TEAE of severe intensity.
Injection-site reactions were reported for 46 of 227
(20.3%) participants, with most [45 of 46 (97.8%)]
reported as mild to moderate. One (0.4%) participant expe-
rienced a single instance of a severe injection-site reaction
of transient pain considered to be related to treatment;
the event occurred on day 1 of treatment and was resolved
the same day with no change in study drug. No other
TEAEs of severe intensity were related to the injection site
or to the study drug.
Laboratory-related TEAEswere reported for four (1.8%)
participants. None were serious or severe in intensity,
related to the study drug or led to discontinuation of the
study drug. No vital signs or C-SSRS results indicated
clinically meaningful concerns. In total, three (1.9%)
participants had ECG-related TEAEs not considered related
to the study drug; these included QRS complex abnormal
and moderate QT prolonged (n = 1), myocardial ischaemia
(n = 1) and ventricular tachycardia (n = 1).
A total of 5 (2.2%) participants discontinued the study
drug due to TEAEs. Two (0.9%) participants discontinued
due tomild injection-site TEAEs related tomedication (pain
and swelling in one participant and erythema, swelling
and pruritus in one participant). One (0.4%) participant
discontinued due to multiple non-injection-site TEAEs,
including two SAEs (road traffic accident andmultiple inju-
ries) considered unrelated to treatment. An additional two
participants discontinued due to TEAEs of pain in extremity
(n = 1) and abnormal QRS complex and prolonged QT on
ECG (n = 1).
Three pregnancies occurred during the study; two par-
ticipants elected to terminate the pregnancy and remain in
the study. One participant withdrew from the study and
carried the pregnancy to term. The infant was born with
Table 4 Summary of treatment-emergent adverse events (overall safety population).
Category Converted from SL BPN n = 190 New to BPN treatment n = 37 Overall N = 227
≥ 1 TEAE 131 (68.9) 12 (32.4) 143 (63.0)
≥ 1 drug-related TEAE 58 (30.5) 2 (5.4) 60 (26.4)
Injection-site TEAE 43 (22.6) 2 (5.4) 45 (19.8)
Non-injection-site TEAE 23 (12.1) 1 (2.7) 24 (10.6)
≥ 1 severe TEAE 13 (6.8) 2 (5.4) 15 (6.6)
Deaths 0 0 0
≥ 1 SAE 10 (5.3) 2 (5.4) 12 (5.3)
≥ 1 drug-related SAE 0 0 0
Hospitalizations 9 (4.7) 1 (2.7) 10 (4.4)
TEAEs leading to discontinuations 4 (2.1) 1 (2.7) 5 (2.2)
TEAEs in ≥ 5% of participants
Injection-site pain 33 (17.4) 2 (5.4) 35 (15.4)
Injection-site swelling 25 (13.2) 2 (5.4) 27 (11.9)
Injection-site erythema 20 (10.5) 1 (2.7) 21 (9.3)
Headache 18 (9.5) 0 18 (7.9)
Nasopharyngitis 17 (8.9) 1 (2.7) 18 (7.9)
Nausea 16 (8.4) 0 16 (7.0)
Urinary tract infection 9 (4.7) 3 (8.1) 12 (5.3)
Vomiting 12 (6.3) 0 12 (5.3)
Data presented as n (%). BPN= buprenorphine; SL BPN= sublingual buprenorphine; TEAE= treatment-emergent adverse event; SAE = serious adverse event.
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neonatal opioid abstinence syndrome (NAS), attributed to
BPN use during the pregnancy (CAM2038 during the first
5 weeks and subsequently SL BPN prescribed for 8 months
prior to birth). The infant was treated with morphine for
12 days starting day 3 after delivery; NAS was considered
resolved 17 days after delivery.
Retention
Rates of treatment retention were high; 188 of 227
(82.8%) participants completed 24 weeks of treatment
and 167 of 227 (73.6%) completed the treatment period
(Fig. 2a). The mean (SD) and median duration of overall
treatment was 39.1 (16.2) and 48 weeks, respectively.
Substance use, withdrawal and cravings
All new-to-treatment participants were positive for illicit
opioids at baseline; the percentage of the composite of illicit
opioid-negative urine samples and self-reports at last study
visit increased to 63.0% (17 of 37) at the end of the treat-
ment period. For participants converted from SL BPN, the
percentage of participants negative for illicit opioids in-
creased from 78.4% on day 1 to 82.8% (111 of 190) at
the end of the treatment period (Fig. 2b). Participant self-
reports of no illicit opioid use increased from 0% on day 1
to 81.5% at the end of the treatment period for new-to-
treatment participants and was high on day 1 for partici-
pants converted from SL BPN (92.1%), and remained high
through the end of treatment period (93.2%). The percent-
age of participants with positive samples for other drugs of
abuse, including amphetamines, barbiturates, benzodiaze-
pines, cannabinoids, cocaine, ethanol and phencyclidine,
remained low and generally stable from baseline to the
end of the treatment.
Mean COWS and SOWS scores decreased from
baseline to the end of the treatment for both converted
and new-to-treatment participants (Fig. 2c, Table 5).
Craving, measured by both mean ‘need to use’ and ‘desire
to use’ VAS scores, also decreased from baseline to the end
of the treatment for converted and new-to-treatment
participants (Fig. 2d, Table 5).
Patient-reported experience measures
A total of 110 (48.4%) participants completed surveys at
month 6 (34 participants new to treatment and 76 con-
verted from SL BPN); 162 of 227 (71.4%) participants
completed surveys rating the importance of various
characteristics regarding BPN treatment and participant
satisfaction with CAM2038 relative to previous treatment
with SL BPN at 12 months (29 participants new to treat-
ment and 133 converted from SL BPN). In both groups,
for all items on the survey, for the importance of various
characteristics regarding treatment with BPN including
ease of travel, daily adherence, privacy, lack of need for
daily medication or regular trips to pharmacy, accidental
paediatric exposure and access by others to medications,
median scores for patient satisfaction with CAM2038
treatment at 6 and 12months were 7.0 (‘extremely impor-
tant’), except for a median score of 6.5 for ‘prevents other
access to my medication’ at month 6 for new-to-treatment
participants (Supporting information, Table S1). Results
were similar for participants converted from SL BPN and
those new to treatment. For participant satisfaction, 91 of
133 (68.4%) participants converted from SL BPN
responded that CAM2038 was ‘much better’ than their
previous treatment with SL BPN, while four participants
(3.0%) responded that CAM2038 was ‘much worse’ than
their previous treatment.
DISCUSSION
CAM2038 weekly and monthly was well tolerated in this
Phase 3, open-label, multi-centre, 48-week safety study
and demonstrated a safety profile consistent with the
known profile of BPN [20]. The majority of TEAEs were
mild or moderate in intensity. There were few injection-site
TEAEs leading to discontinuations, and the majority of
injection-site TEAEs, occurring in 20% of participants,
were mild or moderate pain, swelling and erythema. There
were no unexpected safety findings or drug-related SAEs.
The overall incidence of TEAEs was numerically and statis-
tically higher in participants converted from SL BPN rela-
tive to new to treatment (P = 0.0001). However, no
difference was seen in severe TEAEs, SAEs, hospitalizations
or discontinuation. The reason for the relatively low num-
ber of TEAEs in the new to treatment group is unknown.
Approximately equal numbers of participants started
the study with weekly and monthly CAM2038, depending
on treatment status at baseline. Additionally, investigators
were able to treat with only weekly injections, only
monthly injections, weekly then transitioning to monthly
or monthly transitioning to weekly. As CAM2038 was
available in multiple doses, this allowed the flexibility to
individualize treatment based on clinical response.
Temporary dose adjustments with 8-mg CAM2038, while
allowed, were infrequent, occurring as only 5.8% of the
total number of CAM2038 injections given. New-to-
treatment participants were retained in treatment at least
as well as those converted from SL BPN, suggesting that
CAM2038 is suitable for new-to-treatment patients as well
as those converting from SL BPN.
For the secondary end-point of effectiveness, measures
of opioid withdrawal and cravings were well controlled
following initiation of CAM2038. Composite self-report
and urine toxicology measures of illicit opioid use were
63.0% at the end of the treatment for participants new to
treatment and 82.8% for participants converted from SL
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BPN. The majority of participants converted from SL BPN
indicated that CAM2038was ‘much better’ than their pre-
vious treatment.
Rates of treatment retention were high, with 167 of
227 (73.6%) total enrolled participants completing the
48-week treatment period. Our findings are favourable
compared with other recent studies of long-term daily
BPN. One large-scale randomized study reported retention
rates of 46% after 6 months, with illicit opioid-negative
urine samples in approximately 60% of participants [21].
In another recent 24-week extension study of daily BPN,
the retention rate was 44%, and 76% of participants
provided illicit opioid-negative urine samples at the end of
the study [22]. Other studies reported treatment retention
of approximately ≤ 60% at 6 months with daily BPN
[23,24]. As demonstrated in this study, CAM2038 weekly
and monthly may provide additional treatment retention
benefits, as demonstrated by high retention rates at 24
and 48 weeks of treatment. This long-term study also rein-
forces previous safety and efficacy findings from earlier
studies of CAM2038 [15].
Strengths of the study include a naturalistic, open-label
design with flexible dosing and visit frequency, conducted
across multiple geographies, and in patients initiating
BPN treatment as well as converted from daily BPN. Base-
line characteristics were representative of the population of
participants with moderate or severe OUD. Additionally,
the protocol allowed clinicians and participants
a
b
Figure 2 Efficacy measures, including (a) treatment period completion (participants who had day 337 visit); (b) percentage of urine samples and self-
reports negative for illicit opioid use (n=participants who provided a urine sample); (c) scores for withdrawal, based on clinical opioidwithdrawal scale
scores; and (d) need to use visual analogue scale scores. COWS= clinical opioid withdrawal scale; SL BPN/NX= sublingual buprenorphine/naloxone;
VAS = visual analogue scale
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considerable autonomy in dosing and treatment condi-
tions, reflecting real-world conditions. Limitations include
a lack of explicit directions concerning dosage increases
for administration of supplemental BPN. Because the main
purpose of this study was to examine the safety and accept-
ability of long-term treatment with CAM2038, the design
did not include a control group. Some outcomes were
collected by self-report to clinicians. No data were collected
on broader psychosocial or quality-of-life outcomes.
CONCLUSION
In this study, CAM2038 was well tolerated, retained
participants in treatment for the 48-week study and
c
d
Figure 2 Continued
Table 5 Change in mean scores for withdrawal and craving from baseline to end of treatment.
Converted from SL BPN New to BPN treatment
Baseline End of treatment Baseline End of treatment
COWSa 2.0 (2.7) 1.4 (2.3) 10.6 (3.7) 0.3 (0.5)
SOWSb 4.7 (8.1) 3.3 (6.3) 27.1 (15.3) 3.9 (8.0)
Desire to use VASc 11.7 (24.2) 6.4 (16.5) 74.8 (24.8) 2.8 (6.2)
Need to use VASc 11.7 (23.8) 5.4 (14.3) 76.3 (24.9) 5.3 (15.9)
Data presented as mean (SD). BPN = buprenorphine; COWS = Clinical Opioid Withdrawal Scale; SD = standard deviation; SL BPN = sublingual
buprenorphine; SOWS = Subjective Opioid Withdrawal Scale; VAS = visual analogue scale. aScore ranges from 0 to 48. bScore ranges from 0 to 64. c100-
mm scale.
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had a systemic safety profile consistent with the known
profile of BPN. CAM2038 weekly and monthly were ef-
fective in reducing and maintaining low opioid with-
drawal and cravings scores, and the treatment was
associated with a high percentage of illicit opioid-free
urine samples and self-reports from treatment initiation
throughout maintenance. Participant retention and
abstinence appeared similar or compared favourably with
recent studies of daily SL BPN, suggesting that this long-
acting injectable BPN may be a useful addition to the ar-
mamentarium for treatment of OUD. Future research
should examine types of patients who may particularly
benefit from a long-acting injection. Patients having
difficulty adhering to daily sublingual dosing would be
promising candidates.
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